Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Nikolina Bakali
Observed name:
N. Bakali
Institution:
Barts Cancer Institute
Observed institution:
Barts Cancer Institute
ORCID:
0009-0000-3006-5217
Observed ORCID:
0009-0000-3006-5217
OpenAlex ID:
A5116548242
Data from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Figure 1 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Figure 4 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Figure 8 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Supplementary Table 1 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Supplementary Figure 8 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
PDF
Figure 3 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Supplementary Figure 3 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
PDF
Figure 7 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Supplementary Table 2 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Supplementary Figure 6 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
PDF
Supplementary Figure 9 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
PDF
Supplementary Figure 4 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Supplementary Figure 2 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
PDF
Figure 5 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Figure 6 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Supplementary Figure 5 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
PDF
Supplementary Figure 7 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
PDF
Figure 2 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
Supplementary Figure 1 from Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control
2025
·
Helen Hockings
, Eszter Lakatos
, et al.
PDF
29P BRCA1 reversion mutations confer a fitness benefit to PARP inhibitor-resistant subclones in high grade serous ovarian cancer models
2025
·
M.A. Khan
, A. Hall
, et al.
·
ESMO Open
PDF
Show more works
View as search
Works count:
21
Citation count:
H-index:
I10-index:
Year
Topic
Type